Results 131 to 140 of about 7,344,621 (307)

Premium policy? Getting better value from the PBS [PDF]

open access: yes, 2015
Overview: Poor implementation of a policy to get better value for PBS spending is costing government $320 million a year and raising questions about pharmaceutical industry involvement in drug pricing. The therapeutic group premium policy, introduced in
Stephen Duckett, Peter Breadon
core  

Epigenetic Silencing of CYYR1 Promotes Lung Adenocarcinoma Progression Through TRIM21‐Dependent Regulation of HMMR Stability

open access: yesAdvanced Science, EarlyView.
CYYR1 as an epigenetically dysregulated tumor‐suppressive factor that influences oncoprotein stability through TRIM21‐dependent HMMR regulation and reveals a potential therapeutic vulnerability in CYYR1‐deficient LUAD. The graphical illustration was created using FigDraw (www.figdraw.com).
Fengsheng Dai   +15 more
wiley   +1 more source

Stigma related to illicit drug use: Impact on health and community safety

open access: yesJournal of Community Safety and Well-Being
Public discourse on illicit drug use is frequently characterized by hostility, blame and stigma. This article examines how that stigma is produced and sustained, particularly through dehumanizing portrayals and the positioning of people who use drugs as
Lisa McNally
doaj   +1 more source

Will drug use rise? Exploring a key concern about decriminalising or regulating drugs. [PDF]

open access: yes, 2016
This report argues that this rationale for continuing with an enforcement-led approach to drugs is poorly supported by empirical research, and that alternative policies – in particular the decriminalisation of personal drug possession or the introduction
Murkin, George
core  

ERα–PADI4–CXCL8 Axis Drives MDSC‐Mediated Immune Evasion in Anaplastic Thyroid Carcinoma

open access: yesAdvanced Science, EarlyView.
MAPK‐driven ligand‐independent ERα activation drives PADI4 transcription and translation. This enzyme then modifies CXCL8 chemokines through citrullination, generating a potent chemoattractant gradient specifically for myeloid‐derived suppressor cells.
Dongdong Zhang   +5 more
wiley   +1 more source

Políticas de (des)criminalização das drogas: uma análise comparativa dos modelos regulatórios brasileiro e português

open access: yesRevista Crítica de Ciências Sociais
Beyond the debate on drugs as a concern for international security, this paper incorporates perspectives on well-being and public health as “alternatives” that may contribute to the promotion of peace.
Luan do Nascimento Silva
doaj   +1 more source

Wearable E‐Textiles for Cardiovascular Monitoring: Materials, Devices, and Integrated Systems

open access: yesAdvanced Science, EarlyView.
The graphical abstract highlights the role of conductive materials and textile fabrication techniques in enabling smart textiles for cardiovascular applications. It showcases textile‐based ECG monitoring, pulse sensing, hemodynamic monitoring, and cardiovascular tissue engineering, while emphasizing the challenges and design considerations that govern ...
Bangul Khan   +3 more
wiley   +1 more source

Drug policy: need for radical change?

open access: yes, 2011
What began as a heroin problem in inner-city Dublin in the 1980s has now spread like a cancer throughout Irish society. A wide variety of drugs, from cannabis to heroin to cocaine and on to crack cocaine, are now available in almost every town and ...
McVerry, Peter
core  

Drug Repurposing for Treating NCOR‐Related Intellectual Disability

open access: yesAdvanced Science, EarlyView.
An autism‐associated NCOR1 heterozygous mutation upregulates NRGs and activates NRG backward signaling in hypothalamic GABAergic neurons in mouse models, leading to Gabra2 downregulation and cognitive deficits, which can be therapeutically targeted by repurposing FDA‐approved drugs.
Yan Kong   +15 more
wiley   +1 more source

Optimal Drug Policy in Low-Income Neighborhoods [PDF]

open access: yes
Part of the debate over the control of drug activity in cities is concerned with the effectiveness of implementing demand- versus supply-side drug policies.
N. Edward Coulson   +2 more
core  

Home - About - Disclaimer - Privacy